Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update

$Psyence Biomedical(PBM.US)$ NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that its Australian subsidiary, Psyence Australia Pty Ltd. ("Psyence Australia"), has entered into a partnership with Fluence, a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd ("iNGENū"), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial. The trial will explore the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for the treatment of Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.

According to Lancet Oncology, Adjustment Disorder affects as many as 19% of patients following a life-limiting cancer diagnosis. With symptoms of depression and anxiety that severely impact quality of life for patients, Adjustment Disorder ranks among the seven most frequent psychiatric disorders diagnosed in the world, according to the World Health Organization (WHO).
Fluence's highly credentialed and widely published faculty members are recognized as the global experts in professional psychedelic therapy education; psychiatrists, psychologists, psychotherapists, physicians, and nurse practitioners have completed its comprehensive certification programs. Fluence is authorized by the American Psychological Association (APA), the National Association of Social Workers (NASW), and other professional organizations as a provider of professional continuing education for clinicians.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
2
Translate
Report
3214 Views
Comment
Sign in to post a comment
1833Followers
30Following
22KVisitors
Follow